Financial Review: Flora Growth (NASDAQ:FLGC) vs. iRadimed (NASDAQ:IRMD)

by · The Markets Daily

Flora Growth (NASDAQ:FLGC – Get Free Report) and iRadimed (NASDAQ:IRMD – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.

Profitability

This table compares Flora Growth and iRadimed’s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Flora Growth-32.03%-64.02%-34.46%
iRadimed26.70%23.45%20.36%

Analyst Recommendations

This is a summary of recent recommendations for Flora Growth and iRadimed, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Flora Growth10001.00
iRadimed02312.83

iRadimed has a consensus price target of $120.00, indicating a potential upside of 42.94%. Given iRadimed’s stronger consensus rating and higher probable upside, analysts plainly believe iRadimed is more favorable than Flora Growth.

Institutional and Insider Ownership

36.0% of Flora Growth shares are held by institutional investors. Comparatively, 92.3% of iRadimed shares are held by institutional investors. 2.3% of Flora Growth shares are held by insiders. Comparatively, 34.6% of iRadimed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Flora Growth has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500. Comparatively, iRadimed has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.

Earnings and Valuation

This table compares Flora Growth and iRadimed”s gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Flora Growth$57.61 million0.06-$15.91 million($32.49)-0.10
iRadimed$86.34 million12.43$22.48 million$1.7946.90

iRadimed has higher revenue and earnings than Flora Growth. Flora Growth is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Summary

iRadimed beats Flora Growth on 14 of the 15 factors compared between the two stocks.

About Flora Growth

(Get Free Report)

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.

About iRadimed

(Get Free Report)

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.